Abstract
BackgroundImmunotherapy with monoclonal antibodies that block specific immunological check-points has revolutionized the treatment of some forms of cancer, such as melanoma. A new group of adverse events has emerged with...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
